Cellular Health & Optimization
Leonard Guarente, Chief Scientist
Elysium was co-founded by Dr. Leonard Guarente, director of the Paul F. Glenn Center for Biology of Aging Research at MIT. Since 1982 Guarente has conducted research at MIT on the genetic and molecular basis of aging. As Elysium’s chief scientist, he steers the company's research and product development.
Scientific Advisory Board
Our Scientific Advisory Board is a network of more than 25 world-renowned researchers and clinicians, including eight Nobel Prize-winning scientists, who guide the direction of our company. They are experts in a broad range of subject matter, including biochemistry, neuroscience, and aging.
This network of scientists advises the Elysium team on product identification and development, clinical studies, and ongoing research, accelerating the pace of discovery and ensuring a high level of scientific rigor in the development of Elysium’s products.
Our Human Clinical Trial
Basis is proven to increase NAD+ levels in the blood safely and sustainably. Our double-blind, randomized, placebo-controlled clinical trial, published in November 2017 in the peer-reviewed journal Nature Partner Journals: Aging and Mechanisms of Disease, demonstrated that Basis is proven to increase NAD+ levels in the blood by an average of 40 percent in adults taking the recommended daily dose.
The increase was sustained throughout the duration of the trial. This is the first-ever demonstration that NAD+ levels can be increased and sustained in humans over a period of time.
Why NAD+ Is Essential
NAD+ is a key player in making ATP, the source of energy in the cell.
Our sleep and wake cycle, and everything it entails, depends on NAD+.
We have several built-in systems for fixing errors in our DNA, and these systems need NAD+.